首页 蛋白库 基因库 产品 会员服务
位置：首页 > 产品库 > Toremifene Citrate(FC 1157a)
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
Toremifene Citrate(FC 1157a)
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
Toremifene Citrate(FC 1157a)图片
CAS NO:89778-27-8
规格:≥98%
包装与价格：
包装价格(元)
100mg询价
250mg询价
500mg询价
1g询价
2g询价
10g询价

理化性质和储存条件
Molecular Weight (MW)598.08
FormulaC32H36ClNO8
CAS No.89778-27-8
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 100 mg/mL (167.2 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Other info

Chemical Name: (Z)-2-(4-(4-chloro-1,2-diphenylbut-1-en-1-yl)phenoxy)-N,N-dimethylethan-1-amine 2-hydroxypropane-1,2,3-tricarboxylate

InChi Key: IWEQQRMGNVVKQW-OQKDUQJOSA-N

InChi Code: InChI=1S/C26H28ClNO.C6H8O7/c1-28(2)19-20-29-24-15-13-23(14-16-24)26(22-11-7-4-8-12-22)25(17-18-27)21-9-5-3-6-10-21;7-3(8)1-6(13,5(11)12)2-4(9)10/h3-16H,17-20H2,1-2H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/b26-25-;

SMILES Code: ClCC/C(C1=CC=CC=C1)=C(C2=CC=C(OCCN(C)C)C=C2)\C3=CC=CC=C3.O=C(CC(C(O)=O)(O)CC(O)=O)O

SynonymsNSC-613680; NK-622; FC 1157a; NSC-613680; FC-1157a; NSC 613680; NSC613680; FC1157a; Fareston; NK 622
实验参考方法
In Vitro

In vitro activity: Toremifene (7.5 mM) causes approximately 60% of the cells to exhibit morphologic characteristics typical of cells undergoing programmed death, or apoptosis in human breast cancer cells. Toremifene (5-10 mM) results in elevated levels of TRPM-2 and TGF beta 1 mRNAs in in vitro or in vivo grown tumor cells. Toremifene causes growth inhibition of estrogen-sensitive breast cancer cells by inducing some cells to undergo apoptosis and by inhibiting other cells from entering mitosis. Toremifene induces a dose-dependent level of adducts that is lower than that observed for TAM. Toremifene significantly enhances endogenous DNA adduct formation. Toremifene affects the cell turnover by inhibiting mitotic activity and modifying abundant spontaneous apoptosis in DMBA-induced rat mammary carcinoma.

In VivoToremifene, at the highest tested dose, increases the incidence of hepatocellular carcinomas in the DEN-initiated groups to a level one-third that observed with Tamoxifen administration to DEN-initiated rats. Toremifene increases the incidence of hypernephromas in previously DEN-initiated rats. Toremifene results in aneuploidy in 50% of the cells examined and compared with the 85% level induced by Tamoxifen in female Sprague-Dawley rats.
Animal modelRats
Formulation & Dosage
References

J Natl Cancer Inst. 1993 Sep 1;85(17):1412-8; Carcinogenesis. 1995 Nov;16(11):2733-41.

 
 
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024